JP2024546964A5 - - Google Patents
Info
- Publication number
- JP2024546964A5 JP2024546964A5 JP2024536003A JP2024536003A JP2024546964A5 JP 2024546964 A5 JP2024546964 A5 JP 2024546964A5 JP 2024536003 A JP2024536003 A JP 2024536003A JP 2024536003 A JP2024536003 A JP 2024536003A JP 2024546964 A5 JP2024546964 A5 JP 2024546964A5
- Authority
- JP
- Japan
- Prior art keywords
- rna construct
- pharmaceutical composition
- protein
- rna
- iip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202118464 | 2021-12-17 | ||
| GB2118464.3 | 2021-12-17 | ||
| PCT/GB2022/053275 WO2023111592A1 (en) | 2021-12-17 | 2022-12-16 | Rna construct |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546964A JP2024546964A (ja) | 2024-12-26 |
| JP2024546964A5 true JP2024546964A5 (https=) | 2025-12-23 |
Family
ID=84627358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536003A Pending JP2024546964A (ja) | 2021-12-17 | 2022-12-16 | Ｒｎａ構築物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250051798A1 (https=) |
| EP (1) | EP4448774A1 (https=) |
| JP (1) | JP2024546964A (https=) |
| KR (1) | KR20240118877A (https=) |
| CN (1) | CN118715325A (https=) |
| AU (1) | AU2022416947A1 (https=) |
| WO (1) | WO2023111592A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202313445D0 (en) | 2023-09-04 | 2023-10-18 | Imperial College Innovations Ltd | Rna molecule |
| WO2025189168A1 (en) * | 2024-03-08 | 2025-09-12 | SunVax mRNA Therapeutics Inc. | Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
| GB201908729D0 (en) * | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
-
2022
- 2022-12-16 CN CN202280091565.8A patent/CN118715325A/zh active Pending
- 2022-12-16 WO PCT/GB2022/053275 patent/WO2023111592A1/en not_active Ceased
- 2022-12-16 AU AU2022416947A patent/AU2022416947A1/en active Pending
- 2022-12-16 EP EP22830606.4A patent/EP4448774A1/en active Pending
- 2022-12-16 KR KR1020247023956A patent/KR20240118877A/ko active Pending
- 2022-12-16 US US18/721,163 patent/US20250051798A1/en active Pending
- 2022-12-16 JP JP2024536003A patent/JP2024546964A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537562A5 (https=) | ||
| JP2023541108A5 (https=) | ||
| JP2024546964A5 (https=) | ||
| JP2022512912A5 (https=) | ||
| JP2023523414A5 (https=) | ||
| JP2023509966A5 (https=) | ||
| CN118147171B (zh) | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 | |
| US10653769B2 (en) | iDNA vaccines and methods for using the same | |
| JP2024539089A5 (https=) | ||
| TW202108598A (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| JP2023523413A5 (https=) | ||
| Rzymski et al. | Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches | |
| CN118086288A (zh) | 多顺反子的自放大rna及制备方法 | |
| Chandarana et al. | A review of clinical trials of cancer and its treatment as a vaccine | |
| Ozkan | How close are we to a COVID-19 vaccine | |
| CN115989321B (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| JP2024542126A5 (https=) | ||
| US20260109975A1 (en) | Self-replicating rna and use thereof | |
| CN107201370A (zh) | 一种dna分子与重组病毒及它们的制备方法和用途 | |
| CN101748151B (zh) | 一种重组人丙肝病毒抗原腺病毒载体及其应用 | |
| CN121586776A (zh) | 自扩增核酸分子及其应用 | |
| CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
| CN119679932A (zh) | 效能延长型新冠病毒自复制核酸疫苗 | |
| CN101220373A (zh) | 一种重组病毒载体及其应用 | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells |